Christine Debouck, PhD
Molecular Biology & Biomarker Advisor
Dr. Christine Debouck joined the Empire Discovery Institute Scientific Advisory Board in May 2019. She is currently President of Ardennes Biosciences, a consulting company advising on pharmaceutical research and biomarkers. She brings over 30 years of experience in target validation, diseases & drugs mechanistic characterization in preclinical and clinical development, including biomarker discovery across all phases of drug R&D in all therapeutic areas.
Prior to consulting, Christine was Senior Vice President, Genetics Research, GlaxoSmithKline, where she led cutting edge functional genomics. She first joined SmithKline & French as a post-doc and soon led the AIDS Drug Discovery Program where she discovered the proteolytic activity of HIV protease. After leading several company drug R&D Programs, Christine led the SB/GSK Human Genome Program.
Christine received her B.Sc. degree in Zoology-Molecular Biology, summa cum laude from the University of Brussels-Belgium (ULB), Department of Genetics. She then earned her Ph.D. summa cum laude from ULB, studying the co-regulation of prokaryotic transcription and translation. Christine currently advises start-up biotechnology companies, the BioMotiv accelerator, the Bill & Melinda Gates Foundation, the ADDF Foundation, the Global Health Innovative Technology Fund (Japan), the Grand Challenges Canada global initiative, and the European Commission.
